Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children

Inclusion Criteria: 1. Outpatients of both genders aged over 6 months and under 3 years. 2. Clinically confirmed diagnosis of acute viral upper respiratory tract infections (acute pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, tracheitis, acute viral respiratory infection of multiple and unspecified localization) during the epidemic growth of influenza and ARVI. 3. Dry (non-productive) cough lasting at least 24 hours but not more than 72 hours. 4. Total (day and night) cough severity score of 6 or more. 5. Availability of a patient information sheet and an informed consent form for participation in the clinical trial signed by one of the patient's parents/adoptive parents. Exclusion Criteria: 1. Presence of the following diseases at the time of inclusion in the clinical trial: 1.1 Inflammatory processes in the lower respiratory tract. 1.2 Grade III adenoid hypertrophy. 1.3 Chronic adenoiditis. 1.4 Postnasal drip syndrome. 1.5 Gastroesophageal reflux. 1.6 Bronchial asthma. 1.7 Cystic fibrosis. 1.8 Primary ciliary dyskinesia 1.9 Bronchopulmonary dysplasia 1.10 Malformations of the respiratory and ENT organs 1.11 Other chronic lung diseases. 1.12 Primary/secondary immunodeficiency. 1.13 Oncological disease of any localization. 2. Suspected bacterial infection of any localization, including pneumonia, sinusitis, otitis media. 3. Allergic rhinitis. 4. Bronchial obstruction syndrome. 5. Acute obstructive laryngitis \[croup\] and epiglottitis. 6. Congenital heart defects with hypervolemia in pulmonary circulation. 7. Acute respiratory failure. 8. Inflammatory, degenerative, demyelinating diseases of the central nervous system, polyneuropathies, epilepsy. 9. Exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in a clinical trial. 10. Presence of allergy/hypersensitivity to any components of the medicines used in the treatment. 11. Taking medications listed in the section "Prohibited Concomitant Therapy" within 4 weeks prior to inclusion in the study. 12. Patients whose parents/adoptive parents, from the investigator's point of view, will not comply with observation requirements during the study or with the administration of study drugs. 13. Participation in other clinical trials within 3 months prior to inclusion in this trial. 14. A patient's parent/adoptive parent is related to on-site research personnel directly involved in the trial, or is the immediate family member of the investigator. 'Immediate family members' mean spouses, parents, children, or siblings, whether related or adopted. 15. The patient's parent/adoptive parent is employed by OOO "NPF "MATERIA MEDICA HOLDING", i.e., is an employee of the company, a temporary contract employee, or a designated official responsible for conducting the trial or their immediate family member.